^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Published date:
03/30/2023
Excerpt:
This prospective multicenter study enrolled 70 patients with uHCC who received atezolizumab and bevacizumab (Atez/Bev)….Multivariate analysis identified high pretreatment OPN and high α-fetoprotein levels as independent predictors of PD.
DOI:
10.1007/s00535-023-01985-w